Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05621317 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 15, 2025 (before its estimated November 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study Identification, Study Statusv12
  2. Trial status: Enrolling by Invitation to Active, Not Recruitingv11
  3. Primary completion date: Nov 2024 to Nov 2025
    • Trial status: Recruiting to Enrolling by Invitation
    • Study sites: 11 to 14
    • Study completion date: Jul 2025 to Jun 2027
    v10
  4. Site details revised at 1 of 11 sitesv9
  5. Site details revised at 7 of 11 sitesv8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 5 to 11v7
  2. Site details revised at 3 of 5 sitesv6
  3. Site contacts updated at 1 of 5 sitesv5
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2023 to Feb 9, 2023
    • Site details revised at 5 of 5 sites
    v4
  5. Start date: Dec 2022 to Feb 2023v3
  6. Study sites: 6 to 5
    • Start date: Nov 2022 to Dec 2022
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.
Trial Details
NCT Number NCT05621317
Lead Sponsor Aravax Pty Ltd
Conditions
(from sponsor)		 Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
Related terms Immune System Diseases, Peanut Hypersensitivity
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov